CERN, CHUV and THERYQ join forces for a world first in cancer radiotherapy
CERN, the Centre Hospitalier Universitaire Vaudois (CHUV) and THERYQ (ALCEN Group) have signed an agreement for the world-first development of a revolutionary FLASH radiotherapy device that will use very high energy electron (VHEE) radiation to treat cancers resistant to conventional treatments. The device, based on CERN technology, will be installed at CHUV.
At CERN, part of our mission is knowledge transfer and we actively work to find applications of our breakthroughs outside the domain of particle physics for the benefit of society at large. This collaboration demonstrates how CERN technologies and expertise combined with strong partnerships with experts in other fields can really make an impact.
Mike Lamont, Director for Accelerators and Technology at CERN.
A clinical FLASH facility has been developed, with which large, deep-seated tumors are treated using high-energy electrons. The facility is based on accelerator technology developed for CLIC (Compact Linear Collider) to create a high performance and compact facility that can easily fit on a typical hospital campus.
Walter Wuensch, Project leader at CERN.
As a university hospital, the CHUV is fully committed to research. FLASH therapy embodies the spirit of innovation that drives us in this field. Eager to offer the most effective techniques to patients, we have joined forces with a world-class research center and a cutting-edge industrial partner to solve a medical, physical and technical problem and find innovative solutions to fight cancer.
Pr. Philippe Eckert, Director General of CHUV.
FLASH technology represents real hope for increasing the potential for curing cancers with radiation therapy, and the current stage will enable first crucial clinical developments in this area.
Pr. Jean Bourhis, Head of the Department of Radiation Oncology at CHUV.
THERYQ is honored to contribute its expertise and agility to this project, alongside CHUV and CERN. FLASHDEEP marks a therapeutic revolution, with the potential to significantly increase the number of patients living longer and cancer-free lives.
Ludovic Le Meunier, CEO of THERYQ.